

Supplemental Table 3. Factors associated with ADU (aCL and/or anti-β2GPI >40 U/mL)

Characteristics	ADU- N=120	ADU+ N=48	P	Adjusted OR [95% CI]¶
Age, years ± SD	58.9 ± 15.5	55.2 ± 13.2	0.15	ND
Female, n (%)	107 (89.2)	40 (83.3)	0.31	ND
Smoking, n (%)			0.43	
Current or past	13 (11)	7 (15)		ND
Never	100 (83)	36 (75)		
NA	7 (6)	5 (10)		
SSc type, n (%)			0.80	
Limited	50 (42)	19 (40)		ND
Diffuse	70 (58)	29 (60)		
Disease duration, years ± SD†	7.3 ± 12.7	10.4 ± 15.1	0.19	ND
Modified Rodnan skin score (0–51), mean (Q1, Q3)	6.0 (2.0, 14.5)	14.0 (8.0, 26.0)	<0.001	1.07 [1.02-1.11] (p=0.005)
PAH				
Suspected PAH on echocardiography, n (%)	13 (11)	6 (13)	0.76	ND
sPAP (mmHg), mean ± SD	31.9 ± 14.7	31.5 ± 10.9	0.90	
PAH on RHC, n (%)	8 (7)	4 (8)	0.70	
mPAP (mmHg), mean ± SD	31.8 ± 9.6	29.6 ± 21.8	0.73	
LVEF on echocardiography (%), mean ± SD	65.4 ± 9.8	67.6 ± 6.7	0.23	ND
ILD, n (%)	47 (39)	26 (54)	0.08	ND
FVC, % predicted ± SD	97.3 ± 17.4	88.3 ± 26.9	0.09	ND
DLCO, % predicted ± SD	71 ± 21.2	64.8 ± 20.4	0.14	ND
SSc-related Autoantibodies, n %				
Anticentromere, n (%)	60 (50)	16 (33)	0.05	0.46 [0.44-6.18]
Anti-Scl70, n (%)	35 (29)	25 (52)	0.006	0.10 [0.82-8.61]
aPL, n (%)				
LA	10 (8)	7 (15)	0.22	ND
aCL (only « High » titers)	5 (4)	1 (2)	0.51	ND
IgG	5 (4)	1 (2)	0.54	ND
IgM	0 (0)	0 (0)	-	ND
Anti-β2GPI (only “high” titers)	3 (3)	7 (15)	0.003	5.27 [0.97-28.62] (p=0.054)
IgG	1 (1)	5 (11)	0.003	ND
IgM	1 (1)	3 (7)	0.04	ND
APS, n (%)	4 (3)	3 (6)	0.39	ND
Overall arterial thrombosis history, n (%)	3 (3)	2 (4)	0.61	ND
Overall venous thrombosis history, n (%)	12 (10)	1 (2)	0.08	ND

ND: not done; NA: not available ; SD: standard deviations; Q1/Q3: quartile 1/quartile 3; ADU: active digital ulceration; SSc: systemic sclerosis; PAH: pulmonary arterial hypertension; sPAP: systolic pulmonary arterial pressure; mPAP: mean pulmonary arterial pressure; RHC: right heart catheterization; LVEF: left ventricular ejection fraction; aPL: antiphospholipid antibodies; LA: lupus anticoagulant; aCL: anticardiolipin; β2GPI: Beta2glycoprotein 1; APS: antiphospholipid syndrome; IPD: interstitial pulmonary disease; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide

† Time from first non-Raynaud's symptom

¶ Logistic regression with adjustment for anticentromere, anti-Scl70, mRSS, smoking, presence of LA and/or aCL